Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation ...

Elegen, Nutcracker Therapeutics to pilot cell-free manufacturing process for RNA-based personalized cancer therapeutics: San Francisco Tuesday, July 15, 2025, 11:00 Hrs [IST] Eleg ...

Nutcracker Therapeutics and Elegen see their mission as delivering scalable and low-cost RNA manufacturing for individualized therapies.

DNA makes RNA, RNA makes protein, protein makes phenotype—was the guiding framework for understanding inheritance and disease ...

Background The elimination of HBV covalently closed circular DNA (cccDNA) remains a critical hurdle for chronic hepatitis B (CHB) management. Objective In this investigation, we examined the efficacy ...

Conducts 27% Workforce Reduction, Ceases Operations at Applied DNA Clinical Labs, Positions LineaRx for Growth – STONY BROOK, ...

Researchers discovered a previously unknown function of RNA, potentially opening the door to new ways to treat cancer and neurodegenerative diseases.

From viruses to humans, life makes microproteins that have evaded discovery until now.

DNA templates have also been used to fill a single blank amine site on a PNA or DNA oligomer with the complementary aldehyde nucleobase side-chain using reductive amination. (24−27) Figure 3 shows an ...

IVT of the rrnAP3 + DNA carrying ADP-ribosylation of the template strand exhibited no inhibition of the synthesis of abortive transcripts, although there was some evidence for stalling of the ...

MSK researchers shed new light on G-quadruplexes, a type of secondary DNA structure that has attracted attention as a potential therapeutic target in cancer.

Sequencing DNA by converting it into an accordion molecule Roche’s new sequencing-by-expansion instrument, due to launch in 2026, garners buzz at AGBT conference by Laurel Oldach ...